Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Sterility & contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections.

6,317 FDA drug recalls with this cause, newest first.

This is the single biggest cause in the register by a wide margin. It covers products that had to be sterile - injectables, eye drops, certain ointments - but could not be verified sterile, or were found contaminated during testing. Most of these recalls come from compounding pharmacies and outsourcing facilities after an FDA inspection finds gaps in how sterile products were made. Sterility failures are treated seriously because the products involved have the least room for error, going straight into the bloodstream or the eye.

Class II · Moderate risk

Cyclosporine 2% ophthalmic

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-637-2013
Class II · Moderate risk

Cataract drops

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-635-2013
Class II · Moderate risk

Acetylcysteine 2 % Solution

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-634-2013
Class II · Moderate risk

Acetylcysteine 20 % solution

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-633-2013
Class II · Moderate risk

Acetylcysteine 10 % Solution

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-632-2013
Class II · Moderate risk

Avastin

Lack of Assurance of Sterility; product linked to adverse event reports of endophthalimitis eye infections and FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-918-2013
Class II · Moderate risk

0.9% Sodium Chloride Injection

Lack of Assurance of Sterility: The product is being recall due to the product lot being incorrectly released without meeting product specifications. There is the potential for the solution to leak from the administrative port to the fill tube seal.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7984-36 D-243-2013
Class II · Moderate risk

METRONIDazole Injection

Lack of Assurance of Sterility: There is the potential for the solution to leak from the administrative port to the fill tube seal.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7811-24 D-206-2013
Class II · Moderate risk

0.9% Sodium Chloride Irrigation

Lack of Assurance of Sterility: There is a potential for the solution to leak from the administration port of the primary container.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7972-08 D-176-2013
Class I · High risk

Cyanocobalamin 1000 mcg/ml

Non-Sterility: Green Valley Drugs received positive sterility results from their testing lab on two lots of Methylprednisolone Preservative Free 40 mg/mL injectable suspension and one lot of Cyanocobalamin 1000 mcg/mL injection, 30 mL MDV.

Terminated Sterility / contamination Green Valley Drugs D-322-2013
Class III · Low risk

TORISEL Kit

Lack of Assurance of Sterility; potential that a low level of endotoxins may be present in the diluent vials.

Terminated Sterility / contamination Pfizer Inc. NDC 0008-1179-01 D-219-2013
Class II · Moderate risk

Nalbuphine HCl Injection

Lack of Assurance of Sterility: Complains of a loose crimp applied to the fliptop vial; and a missing stopper and flip cap were received and therefore sterility cannot be assured.

Terminated Sterility / contamination Hospira, Inc. NDC 0409-1467-01 D-096-2013